Abstract 16466: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Iacopo Olivotto,Carolyn Y. Ho,Daniel Jacoby,Steven J. Lester,Matthew T. Roe,Andrew Wang,Jean-Francois Tamby,Joseph Lambing,June Lee,David X. Zhang,Amy J. Sehnert,Stephen B. Heitner

Abstract 16466: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

2018

Iacopo Olivotto
Carolyn Y. Ho
Daniel Jacoby
Steven J. Lester
Matthew T. Roe
Andrew Wang
Jean-Francois Tamby
Joseph Lambing
June Lee
David X. Zhang
Amy J. Sehnert
Stephen B. Heitner

Introduction: Hypertrophic cardiomyopathy, carries substantial lifelong morbidity, often associated with dynamic left ventricular outflow tract (LVOT) obstruction (oHCM). Since its original descrip...

Keywords:

Placebo-controlled study
Obstructive hypertrophic cardiomyopathy
double blind
Diabetes mellitus
Clinical trial
Ventricular outflow tract
Internal medicine
Medicine
Cardiology
Hypertrophic cardiomyopathy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations